Rich Tillyer, Merck
S
Rich Tillyer
Senior Vice President, Worldwide Preclinical Development, Merck
CAREER JOLT: Moved to Manufacturing
YOU DIDN'T KNOW: "I can't swim"
As the head of preclinical development, Rich Tillyer has helped lead Merck's radical redesign of its storied R&D establishment. In this overturning of tradition, his youth—and abundant British charm—have played a critical role. "I think younger leaders are much better at connecting with employees, so that folks can understand the macro decisions we make," he says. "But we also work to keep folks motivated and focused on their mission."
Rich Tillyer
Like other young stars, Tillyer credits his passion in the lab for his fast rise. But in fact, his capacity to embrace change may have been the decisive factor. His biggest break came disguised as his biggest disruption. Six years in and still a self-described "immature chemist," he was yanked out of the lab and installed as support for the president of the manufacturing division. "At first I was reluctant. Here were these big executives and I was running meetings for them," he recalls. But the two-year stint provided a crash course "in what manufacturing's all about, including the marketing and regulatory aspects."
Once back in the lab, he began integrating—gasp!—cost-effectiveness.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.
